Abstract

HYPOTHESIS: PRIMARY: Augmentation of selective serotonin reuptake inhibitor (SSRI) treatment of Obsessive-Compulsive Disorder w/ondansetron at 3 mg daily for 6 weeks will reduce OCD symptoms significantly more than placebo augmentation. SUBSIDIARY: 1) Augmentation w/ondansetron at 3 mg daily for 11 weeks will reduce OCD symptoms significantly more than augmentation for 6 weeks in the same patients (Shorter vs Longer Treatment). 2) Augmentation w/ondansetron at 6 mg daily for 8 weeks will reduce OCD symptoms significantly more than placebo augmentation for 8 weeks in the same patients (Higher Dose vs Placebo). 3) Augmentation w/ondansetron at 6 mg daily will reduce OCD symptoms significantly more than augmentation at 3 mg daily (Higher Dose vs Lower Dose). 4) Withdrawal of ondansetron treatment at 3 mg daily will be associated w/a statistically significant increase in symptoms (Withdrawal Comparison).
SPECIFIC AIMS : 1) Recruit 30 patients w/a DSM-IV diagnosis of OCD into a randomized trial of SSRI plus ondansetron vs SSRI plus placebo. 2) Monitor patient symptoms using weekly Yale Brown Obsessive Compulsive Scale (YBOCS) total score, YBOCS Clinical Global Impression (CGI) and a patient self-rating scales (PSRS, TOUCS). 3) Comparatively analyze treatment conditions for statistically significant changes in YBOCS, patient self-rating scores, and average CGI rating over the course of an 18 week trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000095-40
Application #
6409591
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1977-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
40
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203

  Publications

Kaltenbach, Karol; O'Grady, Kevin E; Heil, Sarah H et al. (2018) Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. Drug Alcohol Depend 185:40-49
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Gilchuk, Pavlo; Knight, Frances C; Wilson, John T et al. (2017) Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with ?-Galactosylceramide: Theory, Practice, and Protocols. Methods Mol Biol 1494:321-352
Sebag, Sara C; Koval, Olha M; Paschke, John D et al. (2017) Mitochondrial CaMKII inhibition in airway epithelium protects against allergic asthma. JCI Insight 2:e88297
Laird, Chris; Burdorf, Lars; Pierson 3rd, Richard N (2016) Lung xenotransplantation: a review. Curr Opin Organ Transplant 21:272-8
Chung, C P; Ormseth, M J; Connelly, M A et al. (2016) GlycA, a novel marker of inflammation, is elevated in systemic lupus erythematosus. Lupus 25:296-300
Towse, Theodore F; Childs, Benjamin T; Sabin, Shea A et al. (2016) Comparison of muscle BOLD responses to arterial occlusion at 3 and 7 Tesla. Magn Reson Med 75:1333-40
Joy, Nino G; Mikeladze, Maia; Younk, Lisa M et al. (2016) Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism 65:1695-1705
Gilchuk, Pavlo; Hill, Timothy M; Guy, Clifford et al. (2016) A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract Infection. Cell Rep 16:1800-9
Jones, Hendrée E; Seashore, Carl; Johnson, Elisabeth et al. (2016) Measurement of neonatal abstinence syndrome: Evaluation of short forms. J Opioid Manag 12:19-23

Showing the most recent 10 out of 515 publications